Clinical

Chi-Med’s surufatinib phase III trial halted early after meeting primary endpoint in advanced pancreatic NET

January 21, 2020

BEIJING – Hong Kong-headquartered Hutchison China Meditech Ltd.’s (Chi-Med) called an early stop to its phase III pivotal study of surufatinib in advanced pancreatic neuroendocrine tumors (NET) in China after it met the predefined primary endpoint of progression-free survival.

Innovent scores first IND for TIGIT antibody and explores PD-1/RNAi combination

January 14, 2020

By Elise Mak

No Comments

China-based Innovent Biologics Inc. will need to get on two new tasks this year: Preparing for the first clinical trial for an anti-TIGIT antibody in China and investigating the combination therapy of its Tyvyt (sintilimab) and Sirnaomics Inc.’s STP-705.

Australia’s Antisense Therapeutics’ phase II DMD trial meets primary endpoints for disease progression

December 31, 2019

By Tamra Sami

No Comments

PERTH, Australia – On the heels of a $1.15 billion deal between Roche Holding AG and Sarepta Therapeutics Inc. for Sarepta’s gene therapy to treat Duchenne muscular dystrophy (DMD), another therapy to treat DMD is emerging from Down Under.

Boehringer Ingelheim quits development of Pharmaxis drug for NASH indication

December 24, 2019

By Tamra Sami

No Comments

PERTH, Australia – Boehringer Ingelheim GmbH is discontinuing development of BI-1467335 for the treatment of nonalcoholic steatohepatitis (NASH) that it acquired from Sydney-based Pharmaxis Ltd. in 2015.

Cautious optimism for Biolinerx’s CXCR4 inhibitor in pancreatic cancer

December 17, 2019

By David Ho

No Comments

HONG KONG – Israel-based Biolinerx Ltd. has unveiled the latest data from its ongoing phase IIa COMBAT/KEYNOTE-202 study at the European Society of Medical Oncology Immuno-Oncology Congress 2019 which evaluates Biolinerx’s BL-8040.

ESMO Asia 2019

Panelists urge better designs, more global focus for phase I trials

November 26, 2019

By David Ho

No Comments

SINGAPORE – While a lot of focus is placed on phase III trials and the subsequent approvals, panelists during the ESMO Asia Congress pointed to the importance of designing the right kind of phase I trials, from reaching global populations to using appropriate endpoints.

ESMO Asia 2019

Quality of life and quality of studies take stage as Takeda reports solid NSCLC findings

November 26, 2019

By David Ho

No Comments

SINGAPORE – Takeda Pharmaceutical Co. Ltd. presented new findings from its phase III ALTA-1L trial evaluating its Alunbrig (brigatinib) vs. crizotinib in adults with advanced anaplastic lymphoma kinase-positive (ALK+) non-small-cell lung cancer (NSCLC) who had not received a prior ALK inhibitor, showing Alunbrig reduced the risk of disease progression or death by 76% after more than two years of follow-up.

Hua Medicine achieves primary efficacy endpoint in phase III trial for type 2 diabetes candidate

November 26, 2019

By David Ho

No Comments

HONG KONG – China-based Hua Medicine (Shanghai) Ltd.’s phase III trial of a potentially first-in-class dual-acting glucokinase activator, dorzagliatin, met its primary efficacy endpoint.

Aslan's varlitinib clinical study for BTC patients failed to meet primary endpoints

November 19, 2019

By Jihyun Kim

No Comments

HONG KONG – Singaporean drugmaker Aslan Pharmaceuticals Ltd. announced top-line data from its pivotal phase III TreeTopp (treatment opportunity with varlitinib (ASLAN-001) in biliary tract cancer) study in second-line biliary tract cancer patients, which failed to meet co-primary endpoints of progression-free survival (PFS) and overall response rate (ORR).

Chinatrials12 Summit

With the help of trial experts, Chinese biotechs set sail for global market

November 13, 2019

By Elise Mak

No Comments

SHANGHAI – Innovation-driven biotech companies are sprouting up in China and they now aim to gain a bigger global presence through conducting clinical trials not just in their home country but also abroad.

Clinical, BioWorld Asia
RSS

Chi-Med’s surufatinib phase III trial halted early after meeting primary endpoint in advanced pancreatic NET

Innovent scores first IND for TIGIT antibody and explores PD-1/RNAi combination

Australia’s Antisense Therapeutics’ phase II DMD trial meets primary endpoints for disease progression

Boehringer Ingelheim quits development of Pharmaxis drug for NASH indication

Cautious optimism for Biolinerx’s CXCR4 inhibitor in pancreatic cancer

Panelists urge better designs, more global focus for phase I trials

Quality of life and quality of studies take stage as Takeda reports solid NSCLC findings

Hua Medicine achieves primary efficacy endpoint in phase III trial for type 2 diabetes candidate

Aslan's varlitinib clinical study for BTC patients failed to meet primary endpoints

With the help of trial experts, Chinese biotechs set sail for global market

Popular Stories

Thiel calls for improving research grant, regulatory processes to enhance scientific innovation

Insulet to launch wearable insulin pump this year, works with Dexcom iCGM for closed loop

China launches price war to reshuffle pharma industry; Bayer cuts prices by 90% to secure market

Novavax developing nanoparticle vaccine for Wuhan coronavirus

Lung cancer treatment options much improved, but resistance remains

BioWorld Premium

Clinical, BioWorld Asia RSS

Popular Stories

BioWorld Premium

Clinical, BioWorld Asia
RSS